A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Trial Profile

A Phase 2 Study of REGN2810, a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Recruiting
Phase of Trial: Phase II

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Cemiplimab (Primary)
  • Indications Squamous cell cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EMPOWER-CSCC 1
  • Sponsors Regeneron Pharmaceuticals
  • Most Recent Events

    • 02 Oct 2017 Planned number of patients changed from 129 to 182.
    • 05 May 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top